TrialInvestigational new drugs2013

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.

Kenneth J Pienta et al.PubMed ↗Publisher ↗

No numbers read from the abstract.